The UK and US have established a major commercial pact that will keep no tariffs on UK pharmaceutical shipments being sold in the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to boost funding on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that duties on these key goods will be held at nothing for a period of the next three years.
This deal is in response to previous threats to hike duties on branded drug imports, with increases mentioned up to one hundred percent.
"This agreement with the UK reinforces the international landscape for innovative medicines and brings much-needed equity to transatlantic drug exports," a release declared.
Commercial Importance
Medicines are one of the the United Kingdom's largest export categories to the America, which is easily the largest market for major companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months to the end of the third quarter, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This value represented 17.4% of all goods exports in that period.
"This guarantee protects jobs, boosts investment and facilitates the UK to emerge as a international leader for biotech and pharma," a minister commented.
Key NHS Changes
The agreement involves several specific changes from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to double overall health service expenditure on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to stay within budget will be capped at 15%. In the past, repayments were more than twenty percent.
Recent Tensions
The pact takes place against a ongoing row between the drug companies and the British authorities over spending levels and NHS adoption.
The disagreement were intensified by claims that American customers were charged several times more for the same drugs than patients in the UK and Europe.
In recent months, several major drug company projects in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS had to invest a greater share on drugs, noting that its spending on drugs had shrunk as a proportion of its resources over the previous ten-year period.
